What front line therapy would you recommend for a patient with CLL on chronic dual antiplatelet therapy?

Given the bleeding risks associated with BTKi, I personally may prefer venetoclax-based therapy if feasible, in treating patients who require dual antiplatelet therapy (DAPT). This is based on safety considerations.

I consider both BTKi-based therapy and venetoclax-based therapy great options for fr...